KRAS and non-small cell lung carcinoma: In addition, we showed that KRAS-mutants or KRAS KD do not affect the expression of ABC transporters including ABCB1, ABCG2, and ABCC1 in NSCLC cells, ruling out the possibility that KRAS-mutant–mediated NSCLC platinum resistance is a result of the dysregulation of ABC transporters.